Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07486791

A Clinical Study on the Effect of Cardiopulmonary Function and Quality of Life in Patients With Acute Coronary Syndrome Complicated by Heart Failure by "Lying-Sitting-Standing" Sequential Baduanjin

This study investigates the effects of a sequential "lying-sitting-standing" Baduanjin intervention on patients with acute coronary syndrome complicated by heart failure. By evaluating cardiopulmonary function and quality of life through indicators such as echocardiography, NT-proBNP, 6MWT, NYHA classification, and SF-36, we aim to compare its efficacy with conventional treatment. The objective is to provide new insights for early cardiac rehabilitation strategies in patients with acute coronary syndrome complicated by heart failure

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Second Hospital of Shanxi Medical

Taiyuan, Shanxi, 030001, China

Location status: Recruiting

Location contact

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients meeting the diagnostic criteria for ACS (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction)
  • Complicated by heart failure during hospitalization
  • Age ≤ 85 years
  • Muscle strength ≥ grade 3
  • No history of mental illness, conscious and able to cooperate independently with this study
  • Voluntarily participate in this study and sign the informed consent form

Exclusion criteria

  • Patients with persistent heart failure symptoms or NYHA functional class IV despite optimal pharmacological therapy;
  • Patients with contraindications to cardiac rehabilitation, such as uncontrolled hypertension, uncontrolled arrhythmias, or hemodynamic instability;
  • Patients with untreated structural heart disease, such as heart failure caused by valvular heart disease or congenital heart disease;
  • Patients in the acute phase of various diseases, such as severe infection, deep vein thrombosis, or severe hepatic or renal failure;
  • Patients with disabilities, bone or joint diseases, or neurological disorders that preclude participation in Baduanjin exercises;
  • Patients with a life expectancy of less than one year;
  • Patients currently participating in other clinical trials.

Treatment and study plan

standard treatment and routine rehabilitation nursing guidance

Behavioral

standard treatment and routine rehabilitation nursing guidance

"Lying-Sitting-Standing" Sequential Baduanjin

Behavioral

"Lying-Sitting-Standing" Sequential Baduanjin

Primary outcomes

  1. Patients were stratified based on their 6-minute walk test distance

    Time frame: From enrollment to the end of the 12-week treatment

    The 6-minute walk test is an objective indicator for evaluating exercise tolerance in patients with heart failure, representing the total distance a patient can walk in 6 minutes. The results are categorized into four grades based on the distance covered: <300 m, 300-374.9 m, 375-449.9 m, and ≥450 m.

  2. NYHA(New York Heart Association)classification of cardiac function

    Time frame: From enrollment to the end of the 12-week treatment

    The New York Heart Association (NYHA) Functional Classification, proposed in 1928 and still in use today, categorizes patients into classes Ⅰ through Ⅳ, with class Ⅰ representing the best condition and class Ⅳ the worst.

  3. Left ventricular ejection fraction (LVEF) on echocardiography

    Time frame: From enrollment to the end of the 12-week treatment

    Ejection fraction is a ratio reflecting the efficiency of cardiac pumping, defined as the percentage of blood volume pumped out by the left ventricle during each contraction (stroke volume, SV) relative to its end-diastolic volume (EDV). It is measured using the Simpson's method on echocardiography.

  4. C-reactive protein levels

    Time frame: From enrollment to the end of the 12-week treatment

    Unit:mg/L

  5. SF-36(ShortForm36HealthSurvey)

    Time frame: From enrollment to the end of the 12-week treatment

    The SF-36 is a generic scale developed by the Boston Health Research Institute in the United States in 1988, based on the Medical Outcomes Study Short-Form (MOS SF) originally devised by Stewart et al. It is used to assess health-related quality of life in populations. The scale contains 36 items and comprehensively evaluates health-related quality of life across eight dimensions: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). Scores for each dimension are converted using specific formulas to a scale of 0 to 100, with higher scores indicating better health status.

  6. NT-proBNP(N-terminal pro-B-type natriuretic peptide)levels

    Time frame: From enrollment to the end of the 12-week treatment

    Unit:pg/ml

  7. FMD(flow-mediated vasodilation)

    Time frame: From enrollment to the end of the 12-week treatment

    Flow-mediated dilation (FMD) is a non-invasive method for assessing vascular endothelial function, based on the mechanism by which endothelial cells respond to changes in shear stress. It uses high-frequency ultrasound (7-12 MHz) to measure the inner diameter of the brachial artery at rest, record the peak blood flow velocity and changes in vessel diameter following reactive hyperemia, and calculate the maximum vasodilatory response. The calculation formula is: FMD = [(post-reactive diameter - baseline diameter) / baseline diameter] × 100%.

  8. ADL(Activities of Daily Living Scale)

    Time frame: From enrollment to the end of the 12-week treatment

    The ADL , which stands for the Activities of Daily Living Scale, was developed by Lawton and Brody in 1969. It is primarily used to assess an individual's ability to perform daily activities. The basic activities of daily living evaluated by this scale include ten items: feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, bed-to-chair transfer, walking on level ground, and stair climbing. The total score is 100 points. Based on the score, functional status is classified into four levels: ≤40 indicates severe dependence; 41-60 indicates moderate dependence; 61-99 indicates mild dependence; and 100 indicates independence.

Sponsors and collaborators

Lead sponsor

Xiling Qi

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 20, 2026
Registry last updated
May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.